I think the one we hear most often has to do with drugs that are currently on the market. Health Canada has performance standards that it needs to meet in reviewing current submissions for new drugs. The division of Health Canada that is responsible for that is the veterinary drugs directorate. When we are talking about trying to either make label changes or approve foreign sites for a manufacturer, we're dealing with a different branch of Health Canada. It's the regulatory operations branch, and it does not have a veterinary-specific team. In that case, we're competing against the needs of the human pharmaceutical world.
I think, in general, the review times for Canada are longer than they are in the United States. That makes things like joint reviews of new drugs difficult, because the U.S. is not willing to wait for Canada to go through its entire review process. As a result, products will either hit the market in the United States first, or they just won't come to Canada at all because there are additional time and resources that are just not worth the return on investment in terms of the market size.